Raymond James raises Rapport Therapeutics price target to $86 from $75
Bullish analyst update, with substantial implied upside at the new target; treat the target as an opinion rather than a forecast.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst update, with substantial implied upside at the new target; treat the target as an opinion rather than a forecast.
What happened, with direct paths to the underlying reporting
Raymond James raised its RAPP price target by about 15%. The new target is well above the posted price of $29.19, though this remains a single analyst opinion.
Target: $86
Posted price: $29.19
Analyst firm: Raymond James
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.